Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M49,279Revenue (TTM) $M6,400Net Margin (%)20.2Altman Z-Score7.7
Enterprise Value $M54,965EPS (TTM) $2.8Operating Margin %22.1Piotroski F-Score5
P/E(ttm)38.1Beneish M-Score-2.5Pre-tax Margin (%)25.5Higher ROA y-yN
Price/Book16.010-y EBITDA Growth Rate %12.5Quick Ratio1.3Cash flow > EarningsN
Price/Sales7.75-y EBITDA Growth Rate %15.1Current Ratio2.8Lower Leverage y-yN
Price/Free Cash Flow132y-y EBITDA Growth Rate %2.9ROA % (ttm)15.7Higher Current Ratio y-yY
Dividend Yield %1.2PEG2.4ROE % (ttm)45.0Less Shares Outstanding y-yY
Payout Ratio %45.0Shares Outstanding M453ROIC % (ttm)19.7Gross Margin Increase y-yY

Gurus Latest Trades with CMXHF

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CMXHF is held by these investors:



CMXHF: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about CMXHF:

    News about CMXHF:

    Articles On GuruFocus.com
    CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourag Oct 12 2017 
    Japan's Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring's Novel Recombinant Sep 28 2017 
    Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Sep 28 2017 
    CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State Sep 19 2017 
    CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] f Sep 14 2017 
    CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI Sep 14 2017 
    Grifols a Leader in High-Demand Plasma Aug 29 2017 
    CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform Aug 28 2017 
    HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patie Jul 25 2017 
    CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Hum Jul 21 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}
    FEEDBACK